2016
DOI: 10.1038/bmt.2015.335
|View full text |Cite
|
Sign up to set email alerts
|

Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(17 citation statements)
references
References 100 publications
(145 reference statements)
0
15
0
Order By: Relevance
“…Roles have also been described for iNKT cells helping to suppress Th1 responses and drive tolerogenic responses to grafts. As an example, following hematopoietic stem cell transfer, the presence of iNKT cells is predictive for survival with a reduction in graft versus host disease (GvHD) in patients and preclinical models ( 8 , 9 , 19 21 ).…”
Section: Overview Of Inkt Cell Biologymentioning
confidence: 99%
See 1 more Smart Citation
“…Roles have also been described for iNKT cells helping to suppress Th1 responses and drive tolerogenic responses to grafts. As an example, following hematopoietic stem cell transfer, the presence of iNKT cells is predictive for survival with a reduction in graft versus host disease (GvHD) in patients and preclinical models ( 8 , 9 , 19 21 ).…”
Section: Overview Of Inkt Cell Biologymentioning
confidence: 99%
“…Other risks include antigen selection issues (e.g., off-tumor on-target) and GvHD caused by TCR mispairing in rTCR-expressing cells and via allogeneic cell therapy ( 67 ). Interestingly, while GvHD is a common concern for both CAR-T and rTCR-T, iNKT cells have been shown in pre-clinical models to suppress, not cause GvHD and are associated with reduced GvHD in the clinic ( 19 21 , 68 , 69 ), making for a potentially safer therapeutic approach. In light of both the promises and drawbacks of CAR-T and rTCR-T cells, there is growing interest in utilizing iNKT cells as an ideal platform for CAR or rTCR therapies (CAR-iNKT or CAR-rTCR).…”
Section: Future Clinical Trials: Car-inkt and Rtcr-inktmentioning
confidence: 99%
“…23 Compared with Treg infusion, iNKT infusion required fewer cells (100 000 iNKT vs 500 000 Treg in the same model) to reach optimal effect. 3,24 In addition, iNKT cells have inherent antiviral and antitumor abilities 25 that are desirable for patients with cGVHD. iNKT cells are persistent in host, as they can be detected in spleen, liver, and lung at least 2 weeks after infusion (not shown).…”
Section: Therapeutic Inkt Cell Infusion Reversed Established Cgvhdmentioning
confidence: 99%
“…The suppression of graft-versus-host-disease (GvHD), while maintaining graft-versus-tumor effect has been shown to be highly dependent on the engraftment of donor iNKT cells, as failure to reconstitute iNKT cells after transplantation strongly correlated with disease relapse ( 84 87 ). Studies into the mechanisms of GvHD suppression show that iNKT cells modulate the overall immune response through production of Th2 cytokines such as IL-4, which in turn dampen inflammatory donor T cells, and promote Treg proliferation against both acute and chronic GvHD ( 88 91 ). These studies therefore highlight an importance function of the Th2 arm of activated iNKT cells in the facilitation of engraftment of allogenic donor cells against recurrence of leukemia.…”
Section: Immunoregulatory and Direct Cytotoxic Activities Of Inkt Celmentioning
confidence: 99%